Aurinia Pharmaceuticals is a commercial stage biopharmaceutical company focused on developing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company received FDA approval in 2021 for their first commercially available drug product. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub in Rockville, Maryland, and focuses its development efforts globally. Please visit our website to learn more about our product.